Department of Anesthesiology and Perioperative Medicine, Division of Pain Medicine, Mayo Clinic, Rochester, MN, USA.
West Virginia University School of Medicine, Charleston, WV, USA.
Neuromodulation. 2021 Jun;24(4):695-699. doi: 10.1111/ner.13326. Epub 2021 Jan 28.
Dorsal root ganglion (DRG) stimulation is an effective treatment option for lower extremity complex regional pain syndrome and other focal pain conditions. However, the patient characteristics that may predict long-term outcomes have not been defined.
This was a retrospective observational study that included 93 patients who were implanted with a DRG stimulator at a single private practice institution. A variety of demographic data was collected. Follow-up results were reviewed from multiple time points more than 12 months. Patients were classified as either "responder" or "nonresponder" status using two different thresholds, "greater than or equal to 50% pain relief" and "greater than or equal to 80% pain relief."
A history of prior chronic opioid use was associated with significantly lower rates of responder status based on both a 50% pain relief threshold and 80% pain relief threshold at the one week to one month, three months, and 12-months visits.
This single-center retrospective study found patients prescribed chronic opioids at the time of DRG stimulator implantation had a higher likelihood of less than 50% pain relief and 80% pain relief at one month, three months, and 12 months follow-up visits.
背根神经节(DRG)刺激是治疗下肢复杂性区域疼痛综合征和其他局灶性疼痛疾病的有效方法。然而,哪些患者特征可能预测长期疗效仍未明确。
这是一项回顾性观察研究,纳入了在一家私人诊所植入 DRG 刺激器的 93 名患者。收集了各种人口统计学数据。对超过 12 个月的多个时间点的随访结果进行了回顾。采用两种不同的阈值(“疼痛缓解≥50%”和“疼痛缓解≥80%”)将患者分为“应答者”或“非应答者”。
基于一周至一个月、三个月和 12 个月随访时的 50%疼痛缓解阈值和 80%疼痛缓解阈值,有慢性阿片类药物使用史的患者应答状态的比例显著较低。
这项单中心回顾性研究发现,在植入 DRG 刺激器时服用慢性阿片类药物的患者在一个月、三个月和 12 个月的随访中,疼痛缓解<50%和 80%的可能性更高。